Table 3.
Univariate and multivariate analysis of prognostic factors in patients (OS)
| Parameters | Univariate | Multivariate | ||||||
|---|---|---|---|---|---|---|---|---|
| Median (months) | 95% CI | HR | 95% CI | p-value | HR | 95% CI | p-value | |
| Age | ||||||||
| ≤ 65 | 15.8 | 10.3–21.4 | 0.91 | 1.59–0.52 | 0.744 | |||
| > 65 | 8.2 | 1.1–15.3 | ||||||
| Sex | ||||||||
| Male | 13.3 | 3.8–22.9 | 0.77 | 0.43–1.38 | 0.375 | |||
| Female | 11.6 | 5.3–17.8 | ||||||
| Smoking status | ||||||||
| Smoker | 22.3 | 16.7–27.9 | 0.62 | 0.28–1.39 | 0.244 | |||
| Never smoker | 11.3 | 5.5–17.0 | ||||||
| Performance status, PS | ||||||||
| PS 2 | 15.8 | 8.8–22.9 | 0.86 | 0.49–1.53 | 0.615 | |||
| PS ¾ | 8.4 | 2.3–14.6 | ||||||
| Mutation | 0.52 | |||||||
| L858R | 11.7 | 7.7–15.6 | 0.67 | 0.27–1.65 | 0.382 | |||
| 19del | 18.1 | 9.1–27.1 | 0.59 | 0.24–1.46 | 0.253 | |||
| Uncommon | 3.5 | 0.5–6.6 | ||||||
| Starting dose | ||||||||
| 40 mg | 17.5 | 11.6–23.4 | 0.59 | 0.34–1.05 | 0.073 | 0.93 | 0.51–1.72 | 0.827 |
| 30 mg | 8.1 | 2.6–13.5 | ||||||
| Metastatic sites | ||||||||
| Lung | ||||||||
| Yes | 10.1 | 4.9–15.2 | 1.26 | 0.72–2.19 | 0.422 | |||
| No | 15.8 | 11.0–20.7 | ||||||
| Liver | ||||||||
| Yes | 3.1 | 0.0–18.5 | 1.85 | 0.97–3.52 | 0.061 | 2.15 | 1.1–4.18 | 0.024 |
| No | 13.8 | 8.9–18.6 | ||||||
| Brain | ||||||||
| Yes | 17.5 | 11.6–23.4 | 0.94 | 0.54–1.64 | 0.838 | |||
| No | 10.8 | 6.7–15.0 | ||||||
| Bone | ||||||||
| Yes | 18.1 | 11.5–24.8 | 0.66 | 0.38–1.15 | 0.147 | |||
| No | 8.4 | 1.7–15.2 | ||||||
| Pleura | ||||||||
| Yes | 8.1 | 0.0–17.8 | 1.59 | 0.90–2.81 | 0.112 | |||
| No | 15.5 | 8.2–22.8 | ||||||
| Adrenal gland | ||||||||
| Yes | 10.1 | 0.0–29.7 | 1.28 | 0.46–3.55 | 0.641 | |||
| No | 12.9 | 8.4–17.3 | ||||||
| Distant lymphadenopathy | ||||||||
| Yes | 15.5 | 0.0–39.8 | 1.11 | 0.47–2.62 | 0.804 | |||
| No | 11.7 | 8.1–15.2 | ||||||
| Dose reduction/interruption | ||||||||
| Yes | 20.3 | 15.8–24.8 | 0.65 | 0.37–1.15 | 0.138 | |||
| No | 8.1 | 0.1–16.1 | ||||||
| Discontinuation, AE-related | ||||||||
| Yes | 17.5 | 0.0–38.6 | 0.59 | 0.23–1.48 | 0.261 | |||
| No | 11.7 | 8.2–15.2 | ||||||
| Clinical tumor response | < 0.001 | < 0.001 | ||||||
| CR/PR | 18.1 | 13.6–22.7 | 0.15 | 0.08–0.3 | < 0.001 | 0.14 | 0.05–0.42 | < 0.001 |
| SD | 20.3 | 0.0–43.5 | 0.14 | 0.05–0.39 | < 0.001 | 0.14 | 0.07–0.30 | < 0.001 |
| PD/NA | 1.5 | 0.0–3.1 | ||||||
| BMI | 1.01 | 0.93–1.10 | 0.867 | |||||
| BSA | 0.33 | 0.02–5.99 | 0.451 | |||||
CR complete response, PR partial response, SD stable disease, PD progressive disease, NA not assessed, AE adverse events, BMI body mass index, BSA body surface area, HR hazard ratio, CI confidence interval, OS overall survival